TCR² is an innovative immunotherapy company developing the next generation of T cell therapies for patients suffering from cancer. Our proprietary TRuC⢠(TCR Fusion Construct) T cells â a novel T cell therapy platform â reprogram the natural T cell receptor complex to recognize and kill cancer cells using the full power of T cell signaling pathways independent of HLA. Source
No articles found.
As a leading genome editing company, Editas Medicine is focused on translating the...
As a leading genome editing company, Editas Med...
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...
Incyte Corporation is a Wilmington, Delaware-ba...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a no...
Bicycle Therapeutics is a clinical-stage biopha...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
We are a late-stage biopharmaceutical company dedicated to bringing transformative...
We are a late-stage biopharmaceutical company d...
Join the National Investor Network and get the latest information with your interests in mind.